Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Durect Corp (DRRX)

Durect Corp (DRRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 355,093
  • Shares Outstanding, K 191,942
  • Annual Sales, $ 18,560 K
  • Annual Income, $ -25,320 K
  • 60-Month Beta 1.66
  • Price/Sales 18.61
  • Price/Cash Flow N/A
  • Price/Book 15.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.02
  • Number of Estimates 3
  • High Estimate -0.01
  • Low Estimate -0.04
  • Prior Year -0.02
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.60 +16.87%
on 10/02/19
2.46 -23.98%
on 09/23/19
+0.12 (+6.86%)
since 09/16/19
3-Month
0.67 +179.10%
on 07/18/19
2.46 -23.98%
on 09/23/19
+1.18 (+171.13%)
since 07/16/19
52-Week
0.46 +306.52%
on 12/28/18
2.46 -23.98%
on 09/23/19
+0.91 (+94.79%)
since 10/16/18

Most Recent Stories

More News
DURECT Announces Completion of Enrollment in its Phase 2a Clinical Trial of DUR-928 in Psoriasis and 50% Enrollment in its Phase 1b DUR-928 Clinical Trial in NASH

DURECT Corporation (Nasdaq: DRRX) today announced that it has completed enrollment in its Phase 2a clinical trial of topical DUR-928 in patients with mild to moderate plaque psoriasis. The company also...

DRRX : 1.87 (+1.08%)
DURECT Announces FDA Advisory Committee Meeting to Review POSIMIR® for the Treatment of Post-Surgical Pain

DURECT Corporation (Nasdaq: DRRX) announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that its Class 2 NDA resubmission for POSIMIR® (bupivacaine extended-release...

DRRX : 1.87 (+1.08%)
DURECT to Present at the 2019 Cantor Fitzgerald Global Health Care Conference

DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, Chief Executive Officer will be presenting at the Cantor Fitzgerald Global Health Care Conference, at the InterContinental New York...

DRRX : 1.87 (+1.08%)
DURECT Announces Positive Data from its Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis

DURECT Corporation (Nasdaq: DRRX) today announced that it has completed the Phase 2a clinical trial of its lead product candidate, DUR-928, in patients with alcoholic hepatitis (AH). The final enrollment...

DRRX : 1.87 (+1.08%)
DURECT Earns $10 Million Milestone Payment for Further Development of a Long-Acting Injectable HIV Investigational Product Utilizing DURECT's SABER® Technology

DURECT Corporation (Nasdaq: DRRX) announced today that further development of a long-acting injectable HIV investigational product utilizing DURECT's SABER® technology has triggered a $10 million milestone...

GILD : 65.35 (+0.08%)
DRRX : 1.87 (+1.08%)
DURECT to Present at the 21st Annual Rodman and Renshaw Global Investment Conference Sponsored by H.C. Wainwright

DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, Chief Executive Officer will be presenting at the 21st Annual Global Rodman and Renshaw Investment Conference, sponsored by H. C....

DRRX : 1.87 (+1.08%)
Durect: 2Q Earnings Snapshot

CUPERTINO, Calif. (AP) _ Durect Corp. (DRRX) on Thursday reported a loss of $7.2 million in its second quarter.

DRRX : 1.87 (+1.08%)
DURECT Corporation Announces Second Quarter 2019 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2019 and provided a corporate update.

DRRX : 1.87 (+1.08%)
Global Postoperative Management Market Latest Trends and Forecast Analysis Up to 2026 with Top Key Players: WEX Pharmaceuticals, Zynerba Pharmaceuticals, Medtronic, Boston Scientific Corporation

This market research report on the worldwide offers a sequential factsheet identifying with the deliberately mergers, acquirements, joint endeavor exercises, and organizations across the board in the market....

BAYRY : 18.2940 (-0.49%)
BSX : 38.18 (-0.73%)
BMY : 51.51 (-0.62%)
DRRX : 1.87 (+1.08%)
LLY : 107.95 (-1.60%)
HYH : 57.25 (+0.07%)
MDT : 108.50 (+0.29%)
MRK : 84.45 (-0.69%)
NVRO : 82.95 (-1.59%)
PFE : 36.34 (-0.44%)
SRNE : 1.73 (+7.45%)
VRX.TO : 30.80 (-3.33%)
ZYNE : 7.96 (+0.51%)
Global Postoperative Management Market 2026 with Top Key Players: WEX Pharmaceuticals, Zynerba Pharmaceuticals, Medtronic, Boston Scientific Corporation

This market report defines the market trends and forecast the upcoming opportunities and threats of the post-operative management market in the next 8 years. Post-operative management involves management...

BAYRY : 18.2940 (-0.49%)
BSX : 38.18 (-0.73%)
BMY : 51.51 (-0.62%)
DRRX : 1.87 (+1.08%)
LLY : 107.95 (-1.60%)
HYH : 57.25 (+0.07%)
MDT : 108.50 (+0.29%)
MRK : 84.45 (-0.69%)
NVRO : 82.95 (-1.59%)
PFE : 36.34 (-0.44%)
SRNE : 1.73 (+7.45%)
VRX.TO : 30.80 (-3.33%)
ZYNE : 7.96 (+0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade DRRX with:

Business Summary

Durect Corp. is pioneering the treatment of chronic diseases and conditions by developing and commercializing pharmaceutical systems to deliver the right drug to the right place in the right amount at the right time. Its pharmaceutical systems combine engineering innovations and delivery technology from...

See More

Key Turning Points

2nd Resistance Point 1.93
1st Resistance Point 1.90
Last Price 1.87
1st Support Level 1.83
2nd Support Level 1.79

See More

52-Week High 2.46
Last Price 1.87
Fibonacci 61.8% 1.70
Fibonacci 50% 1.46
Fibonacci 38.2% 1.22
52-Week Low 0.46

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar